{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:20:55Z","timestamp":1791361255600,"version":"4.3.1"},"reference-count":93,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>There is a well-established relationship between different subsets of idiopathic inflammatory myopathies (IIMs, myositis) and interstitial lung disease (ILD), with lung complications sometimes presenting prior to myopathic manifestations. The subtypes of myositis include those that are strongly associated with ILD, such as polymyositis (PM) and dermatomyositis (DM). Research has shown that in certain patients, these can then be further divided into subtypes using myositis-specific antibodies (MSAs), which are specific for myositis, and myositis-associated antibodies (MAAs), which can be found in myositis in overlap syndromes with other connective tissue diseases (CTDs). Notably, certain MSAs and MAAs are associated with ILD in patients with myositis. The clinical presentations of ILD in patients with myositis can vary widely and can be insidious in onset and difficult to diagnose. As ILD can progress rapidly in some cases, it is essential that clinicians are able to identify and diagnose ILD in patients with myositis. For this reason, the aim of this review is to highlight the clinical features, diagnostic criteria, important histopathologic, laboratory, and radiographic features, and treatment modalities for those patients with myositis-associated ILD.<\/jats:p>","DOI":"10.3390\/jcm13144055","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T11:33:22Z","timestamp":1720697602000},"page":"4055","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Review of Myositis-Associated Interstitial Lung Disease"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7579-8560","authenticated-orcid":false,"given":"Renuka","family":"Kannappan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raagni","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Cichelli","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Brent","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial Lung Disease in Polymyositis and Dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin. Chest Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and Management of Myositis-Associated Lung Disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and Dermatomyositis\u2014(First of Two Parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11926-005-0061-4","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"7","author":"Schnabel","year":"2005","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: Pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/2397198320902667","article-title":"Antisynthetase syndrome: A distinct disease spectrum","volume":"5","author":"Huang","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MCP.0000000000001000","article-title":"Myositis-associated interstitial lung disease","volume":"29","author":"Vu","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Palmucci, S., Di Mari, A., Cancemi, G., Pennisi, I., Mauro, L.A., Sambataro, G., Sambataro, D., Galioto, F., Fazio, G., and Ferlito, A. (2022). Clinical and Radiological Features of Interstitial Lung Diseases Associated with Polymyositis and Dermatomyositis. Medicina, 58.","DOI":"10.3390\/medicina58121757"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: A New Classification of Adult Autoimmune Myositis","volume":"69","author":"Raynauld","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: An overdiagnosed entity","volume":"61","author":"Bronner","year":"2003","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","article-title":"The role of type I interferons and other cytokines in dermatomyositis","volume":"73","author":"Arshanapalli","year":"2015","journal-title":"Cytokine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12955","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: A review","volume":"31","author":"Bolko","year":"2021","journal-title":"Brain Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11926-996-0024-4","article-title":"Pathogenesis of idiopathic inflammatory myopathies","volume":"8","author":"Grundtman","year":"2006","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-009-1316-7","article-title":"Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis","volume":"29","author":"Kim","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","article-title":"Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis","volume":"1184","author":"Mammen","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_20","first-page":"463","article-title":"Polymyositis and dermatomyositis: Novel insights into the pathogenesis and potential therapeutic targets","volume":"19","author":"Lahouti","year":"2015","journal-title":"Discov. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and Dermatomyositis\u2014\u2009(Second of Two Parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_22","unstructured":"Cheeti, A., Brent, L.H., and Panginikkod, S. (2024). Autoimmune Myopathies, StatPearls Publishing LLC."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1503\/cmaj.180947","article-title":"Dermatomyositis","volume":"191","author":"Chu","year":"2019","journal-title":"Can. Med. Assoc. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Autoimmun. Highlights"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archderm.1990.01670250067010","article-title":"Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy","volume":"126","author":"Cox","year":"1990","journal-title":"Arch. Dermatol."},{"key":"ref_26","first-page":"130","article-title":"New Insights into Antisynthetase Syndrome","volume":"11","author":"Cojocaru","year":"2016","journal-title":"Maedica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3949\/ccjm.80a.12171","article-title":"Antisynthetase syndrome: Not just an inflammatory myopathy","volume":"80","author":"Chatterjee","year":"2013","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results from an International Retrospective Multicenter Study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome\u2013much more than just a myopathy","volume":"51","author":"Opinc","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhao, N., Jiang, W., Wu, H., Wang, P., Wang, X., Bai, Y., Li, Y., Tang, Y., and Liu, Y. (2022). Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.872615"},{"key":"ref_32","first-page":"1","article-title":"Diagnosis and treatment of interstitial lung disease related to systemic autoimmune myopathies: A narrative review","volume":"75","author":"Hoff","year":"2023","journal-title":"Reumatismo"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaut.2007.07.005","article-title":"Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation","volume":"29","author":"Katsumata","year":"2007","journal-title":"J. Autoimmun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.30113","article-title":"Role of innate immunity in a murine model of histidyl\u2013transfer RNA synthetase (Jo-1)\u2013mediated myositis","volume":"63","author":"Soejima","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Howard","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19269","DOI":"10.1074\/jbc.C114.571026","article-title":"Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis","volume":"289","author":"Zhou","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101503","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J. Bras. Pneumol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4081\/reumatismo.2020.1275","article-title":"The clinical manifestations at the onset of antisynthetase syndrome: A chameleon with multiple faces","volume":"72","author":"Baccaro","year":"2020","journal-title":"Reumatismo"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Nombel, A., Fabien, N., and Coutant, F. (2021). Dermatomyositis with Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.773352"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur. J. Radiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis","volume":"60","author":"Wu","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e001202","DOI":"10.1136\/rmdopen-2020-001202","article-title":"Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease","volume":"6","author":"Nishina","year":"2020","journal-title":"RMD Open"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.170165","article-title":"HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis","volume":"44","author":"Chen","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/tan.13171","article-title":"Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population","volume":"90","author":"Lin","year":"2017","journal-title":"HLA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief Report: Association of HLA\u2013DRB1*0101\/*0405 with susceptibility to anti\u2013melanoma differentiation\u2013associated gene 5 antibody\u2013positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.41566","article-title":"Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis\/Dermatomyositis\u2013Associated Interstitial Lung Disease","volume":"73","author":"Gono","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bobirca, A., Alexandru, C., Musetescu, A.E., Bobirca, F., Florescu, A.T., Constantin, M., Tebeica, T., Florescu, A., Isac, S., and Bojinca, M. (2022). Anti-MDA5 Amyopathic Dermatomyositis\u2014A Diagnostic and Therapeutic Challenge. Life, 12.","DOI":"10.3390\/life12081108"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: Results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00296-017-3799-x","article-title":"Mortality and prognostic factors in idiopathic inflammatory myositis: A retrospective analysis of a large multicenter cohort of Spain","volume":"37","author":"Joven","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/joim.13607","article-title":"Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis","volume":"293","author":"Jin","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Huapaya","year":"2017","journal-title":"Rheumatology"},{"key":"ref_59","first-page":"347","article-title":"Clinical Characteristics and Prognostic Value of Ro52\/SSA Antibodies in Idiopathic Inflammatory Myopathies","volume":"29","author":"Pepper","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: A single centre cohort study","volume":"40","author":"Zanframundo","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3899\/jrheum.220139","article-title":"Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody\u2013Positive Dermatomyositis Is Highly Associated with Rapidly Progressive Interstitial Lung Disease and Mortality Risk","volume":"50","author":"Lv","year":"2022","journal-title":"J. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"61","author":"Gui","year":"2022","journal-title":"Rheumatology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wells, M., Alawi, S., Thin, K.Y.M., Gunawardena, H., Brown, A.R., Edey, A., Pauling, J.D., Barratt, S.L., and Adamali, H.I. (2022). A multidisciplinary approach to the diagnosis of antisynthetase syndrome. Front. Med., 9.","DOI":"10.3389\/fmed.2022.959653"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11604-020-01030-3","article-title":"Interstitial lung disease in patients with antisynthetase syndrome: A retrospective case series study","volume":"39","author":"Baratella","year":"2020","journal-title":"Jpn. J. Radiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e25816","DOI":"10.1097\/MD.0000000000025816","article-title":"Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies","volume":"100","author":"Jiang","year":"2021","journal-title":"Medicine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0720-048X(03)00094-9","article-title":"Serial chest CT findings in interstitial lung disease associated with polymyositis\u2013dermatomyositis","volume":"49","author":"Bonnefoy","year":"2004","journal-title":"Eur. J. Radiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hervier, B., and Uzunhan, Y. (2019). Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00326"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.55563\/clinexprheumatol\/brvl1v","article-title":"Myositis-associated interstitial lung disease: A comprehensive approach to diagnosis and management","volume":"40","author":"Hallowell","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fujisawa, T. (2021). Management of Myositis-Associated Interstitial Lung Disease. Medicina, 57.","DOI":"10.3390\/medicina57040347"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Allenbach, Y., Guiguet, M., Rigolet, A., Marie, I., Hachulla, E., Drouot, L., Jouen, F., Jacquot, S., Mariampillai, K., and Musset, L. (2015). Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti-Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133702"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"152164","DOI":"10.1016\/j.semarthrit.2023.152164","article-title":"Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies","volume":"59","author":"Vivero","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-Term Treatment with Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the Treatment of Jo1 Antibody\u2013associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of Intravenous Immune Globulin in Dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s10067-021-05794-5","article-title":"Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: A systematic review and meta-analysis","volume":"40","author":"Ma","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti\u2013Melanoma Differentiation\u2013Associated Gene 5\u2013Positive Dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-\u03b3 and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in Amyopathic Dermatomyositis\u2013Associated Interstitial Lung Disease","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated with Antisynthetase Syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41409-023-02086-1","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: A propensity score matching study","volume":"58","author":"Wang","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102941","DOI":"10.1016\/j.jaut.2022.102941","article-title":"Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease","volume":"133","author":"Bay","year":"2022","journal-title":"J. Autoimmun."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/4055\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:13:13Z","timestamp":1760109193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/4055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":93,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13144055"],"URL":"https:\/\/doi.org\/10.3390\/jcm13144055","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}